Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Mini Rev Med Chem ; 12(9): 856-65, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22681253

ABSTRACT

'Biased agonism' refers to the ability of a ligand to selectively recruit different intracellular signaling proteins to elicit distinct phenotypic effects in cells. While conventional G protein-coupled receptor (GPCR) agonism and antagonism can be regarded as modulating the quantity of efficacy, functionally selective or 'biased' ligands qualitatively change the trafficking of information flowing across the plasma membrane. The concept of ligand directed signaling fundamentally raises the potential of pharmacologic agents with novel therapeutic profiles possessing improved therapeutic efficacy or reduced side effects. Currently, there is little experimental evidence that biased ligands offer advantages over conventional agonists/antagonists in vivo. Recent work examining biased agonism at the type I parathyroid hormone receptor (PTH1R) demonstrates that selective activation of G protein-independent arrestin-mediated signaling pathways elicits a physiologic response in bone distinct from that induced by the conventional PTH1R agonist PTH(1-34). While intermittent (daily) administration of PTH(1-34) (teriparitide) is effective in increasing bone formation, PTH(1-34) administration is also associated with increases in bone resorption and a propensity to promote hypercalcemia/hypercalcuria. In contrast, D-Trp12,Tyr34-bPTH(7-34) (PTH-ßarr), an arrestin pathway-selective agonist for the PTH1R, induces anabolic bone formation independent of classic G protein-coupled signaling mechanisms. Unlike PTH(1-34), PTH-ßarr appears to 'uncouple' the anabolic effects of PTH1R activation from its catabolic and calcitropic effects. Such findings offer evidence that arrestin pathway-selective GPCR agonists can elicit potentially beneficial effects in vivo that cannot be achieved using conventional agonist or antagonist ligands.


Subject(s)
Arrestins/agonists , Bone and Bones/drug effects , Osteogenesis/drug effects , Parathyroid Hormone-Related Protein/administration & dosage , Receptor, Parathyroid Hormone, Type 1/agonists , Animals , Arrestins/metabolism , Bone Resorption/prevention & control , Bone and Bones/physiology , Humans , Hypercalcemia/chemically induced , Hypercalcemia/prevention & control , Hypercalciuria/chemically induced , Hypercalciuria/prevention & control , Ligands , Mice , Osteogenesis/physiology , Parathyroid Hormone/administration & dosage , Parathyroid Hormone/metabolism , Parathyroid Hormone-Related Protein/metabolism , Receptor, Parathyroid Hormone, Type 1/metabolism , Signal Transduction/drug effects
2.
J Clin Oncol ; 18(5): 1110-5, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10694564

ABSTRACT

PURPOSE: To determine the primary sources and secondary complications of Staphylococcus aureus bacteremia (SAB) in cancer patients, as well as predictors of outcome in cancer patients with SAB. PATIENTS AND METHODS: Fifty-two patients at Duke University Medical Center met entry criteria between September 1994 and December 1996 for this prospective cohort study involving hospitalized nonneutropenic adult cancer patients with SAB. All subjects were observed throughout initial hospitalization and were evaluated again at 6 and 12 weeks or until death. RESULTS: SAB was intravascular device-related in 42%, tissue infection-related (TIR) in 44%, and unidentifiable focus-related (UFR) in 13%. Seventeen patients (33%) were found to have metastatic infections or conditions, with eight (15%) developing infectious endocarditis (IE). Patients with TIR bacteremia were less likely than other patients to develop IE (4% v 24%, P =.06). The overall mortality rate was 38%, the SAB-related mortality rate was 15%, and the rate of SAB relapse was 12%. Methicillin resistance was not associated with adverse outcome. Inability to identify a point of entry (UFR bacteremia), however, was associated with a higher overall mortality rate (100% v 24%, P =.0006). Furthermore, a 72-hour surveillance blood culture positive for organisms was associated with an increased incidence of IE (P =.0006), metastatic infections or conditions (P =.0002), SAB relapse (P =.038), and SAB-related death (P =.038). CONCLUSION: SAB in cancer patients is associated with significant morbidity from frequent metastatic infections or conditions including IE, as well as considerable mortality. Unknown initial infection site and 72-hour surveillance cultures positive for organisms were predictive of a complicated course and poor final outcome.


Subject(s)
Bacteremia/complications , Neoplasms/complications , Staphylococcal Infections/complications , Adolescent , Adult , Bacteremia/etiology , Bacteremia/mortality , Cohort Studies , Female , Humans , Male , Neoplasms/mortality , Outcome Assessment, Health Care , Prospective Studies , Staphylococcal Infections/etiology , Staphylococcal Infections/mortality , Survival Analysis
3.
J Infect Dis ; 179(5): 1157-61, 1999 May.
Article in English | MEDLINE | ID: mdl-10191218

ABSTRACT

To identify risk factors for relapse among 309 prospectively identified cases of Staphylococcus aureus bacteremia, patients with recurrent S. aureus bacteremia were identified, and pulsed-field gel electrophoresis (PFGE) was performed on isolates from both episodes. PFGE banding patterns from both isolates were identical in 23 patients, consistent with relapsed infection. Patients with PFGE-confirmed relapse were more likely by both univariate and multivariate analyses to have an indwelling foreign body (odds ratio [OR]=18.2, 95% confidence interval [CI]=7. 6-43.6; P<.001), to have received vancomycin therapy (OR=4.1, 95% CI=1.5-11.6; P=.008), or be hemodialysis-dependent (OR=4.1, 95% CI=1. 8-9.3; P=.002) than patients who did not develop recurrent bacteremia. These results suggest that recurrent episodes of S. aureus bacteremia are primarily relapses and are associated with an indwelling foreign body, receiving vancomycin therapy, and hemodialysis dependence.


Subject(s)
Bacteremia/microbiology , DNA, Bacterial/analysis , Electrophoresis, Gel, Pulsed-Field , Staphylococcal Infections/microbiology , Staphylococcus aureus/genetics , Staphylococcus aureus/isolation & purification , Adult , Aged , Bacteremia/prevention & control , Female , Humans , Male , Middle Aged , Prospective Studies , Recurrence , Risk Factors , Staphylococcal Infections/prevention & control
4.
Curr Infect Dis Rep ; 1(2): 129-135, 1999 Jun.
Article in English | MEDLINE | ID: mdl-11095778

ABSTRACT

Staphylococcus aureus bacteremia (SAB) is a serious and growing problem. A longstanding controversy in infectious diseases has centered around the duration of therapy for patients with SAB. Fortunately, the refinement of echocardiography and the creation of new diagnostic criteria have aided in the diagnosis of infective endocarditis in patients with SAB. These advancements have resulted in the development of an algorithm that combines clinical, microbiologic, and echocardiographic findings to stratify patients with SAB into different treatment regimens.

5.
J Mol Recognit ; 10(2): 63-72, 1997.
Article in English | MEDLINE | ID: mdl-9376129

ABSTRACT

Total internal reflection fluorescence microscopy has been used to investigate the binding of the soluble extracellular domain of mouse Fc gamma RII (sFc gamma RII) to an anti-trinitrophenyl monoclonal mouse IgG2b (GK14.1) specifically bound to substrate-supported planar membranes composed of dipalmitoylphosphatidylcholine (DPPC) and trinitrophenylaminocaproyldipalmitoylphosphatidylethanolamine (TNP-cap-DPPE). The equilibrium dissociation constants for sFc gamma RII at GK14.1-coated TNP-cap-DPPE/DPPC planar membranes containing 0.5-25 mol% TNP-cap-DPPE were approximately 1 microM. Total internal reflection with fluorescence photobleaching recovery was used to examine the dissociation kinetics. The fluorescence recovery curves were better described as a sum of two exponentials rather than by one exponential; the rates and fractional recoveries were approximately 1 s-1 (65%) and approximately 0.1 s-1 (35%). The similarity between the values of these equilibrium and kinetic parameters to those previously measured for the binding of IgG in solution to intact mouse Fc gamma RII reconstituted into planar membranes suggests that conformational changes which may occur when IgG is constrained to a membrane surface do not significantly affect the equilibrium or kinetics of IgG-mouse Fc gamma RII binding. The stoichiometry of sFc gamma RII-GK14.1 binding was 1:4, indicating that a significant fraction of the membrane-bound antibodies were not accessible for receptor binding. Possible mechanisms that might underlay the observed heterogeneity in sFc gamma RII-IgG binding kinetics are discussed.


Subject(s)
Antibodies, Monoclonal/metabolism , Immunoglobulin G/metabolism , Membranes, Artificial , Receptors, Antigen, B-Cell/metabolism , Receptors, IgG/metabolism , 1,2-Dipalmitoylphosphatidylcholine , Animals , Binding Sites , Kinetics , Mice , Microscopy, Fluorescence , Phosphatidylethanolamines , Protein Binding , Receptors, IgG/immunology , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...